Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation.

Cremers EMP, de Witte T, de Wreede L, Eikema DJ, Koster L, van Biezen A, Finke J, Socié G, Beelen D, Maertens J, Nagler A, Kobbe G, Ziagkos D, Itälä-Remes M, Gedde-Dahl T, Sierra J, Niederwieser D, Ljungman P, Beguin Y, Ozkurt ZN, Anagnostopoulos A, Jindra P, Robin M, Kröger N.

Leuk Lymphoma. 2019 Oct;60(10):2404-2414. doi: 10.1080/10428194.2019.1594215. Epub 2019 Apr 18.

PMID:
30997844
2.

Activation of NF-κB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes.

Ping Z, Chen S, Hermans SJF, Kenswil KJG, Feyen J, van Dijk C, Bindels EMJ, Mylona AM, Adisty NM, Hoogenboezem RM, Sanders MA, Cremers EMP, Lindenbergh-Kortleve DJ, Samsom JN, van de Loosdrecht AA, Raaijmakers MHGP.

Leukemia. 2019 Feb;33(2):536-541. doi: 10.1038/s41375-018-0267-x. Epub 2018 Oct 12. No abstract available.

3.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

Stevens-Kroef MJ, Olde Weghuis D, ElIdrissi-Zaynoun N, van der Reijden B, Cremers EMP, Alhan C, Westers TM, Visser-Wisselaar HA, Chitu DA, Cunha SM, Vellenga E, Klein SK, Wijermans P, de Greef GE, Schaafsma MR, Muus P, Ossenkoppele GJ, van de Loosdrecht AA, Jansen JH.

Genes Chromosomes Cancer. 2017 Jul;56(7):524-534. doi: 10.1002/gcc.22455. Epub 2017 Mar 31.

PMID:
28236351
4.

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.

Cremers EM, van Biezen A, de Wreede LC, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, Schwerdtfeger R, Volin L, Harhalakis N, Blijlevens N, Nagler A, Kröger N, de Witte T.

Ann Hematol. 2016 Dec;95(12):1971-1978. Epub 2016 Sep 20.

5.

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group.

Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.

6.

Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia.

Zambetti NA, Ping Z, Chen S, Kenswil KJG, Mylona MA, Sanders MA, Hoogenboezem RM, Bindels EMJ, Adisty MN, Van Strien PMH, van der Leije CS, Westers TM, Cremers EMP, Milanese C, Mastroberardino PG, van Leeuwen JPTM, van der Eerden BCJ, Touw IP, Kuijpers TW, Kanaar R, van de Loosdrecht AA, Vogl T, Raaijmakers MHGP.

Cell Stem Cell. 2016 Nov 3;19(5):613-627. doi: 10.1016/j.stem.2016.08.021. Epub 2016 Sep 22.

7.

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Cremers EM, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA, Chitu DA, van der Velden VH, Te Marvelde JG, Klein SK, Muus P, Vellenga E, de Greef GE, Legdeur MC, Wijermans PW, Stevens-Kroef MJ, Silva-Coelho PD, Jansen JH, Ossenkoppele GJ, van de Loosdrecht AA; A study on behalf of the HOVON89 study group.

Haematologica. 2017 Feb;102(2):320-326. doi: 10.3324/haematol.2016.147843. Epub 2016 Sep 22.

8.

Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation of inflammatory programs.

Chen S, Zambetti NA, Bindels EM, Kenswill K, Mylona AM, Adisty NM, Hoogenboezem RM, Sanders MA, Cremers EM, Westers TM, Jansen JH, van de Loosdrecht AA, Raaijmakers MH.

Leukemia. 2016 Sep;30(9):1938-42. doi: 10.1038/leu.2016.91. Epub 2016 Apr 25. No abstract available.

9.

Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.

Cremers EMP, Westers TM, Alhan C, Cali C, Wondergem MJ, Poddighe PJ, Ossenkoppele GJ, van de Loosdrecht AA.

Eur J Cancer. 2016 Feb;54:49-56. doi: 10.1016/j.ejca.2015.11.013. Epub 2015 Dec 22.

PMID:
26720403
10.

Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations.

Alhan C, Westers TM, Cremers EM, Cali C, Ossenkoppele GJ, van de Loosdrecht AA.

Cytometry B Clin Cytom. 2016 Jul;90(4):358-67. doi: 10.1002/cyto.b.21333. Epub 2015 Dec 14.

11.

The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.

Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, van de Loosdrecht AA.

Leukemia. 2016 Mar;30(3):658-65. doi: 10.1038/leu.2015.295. Epub 2015 Oct 27.

PMID:
26503643
12.

Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?

Cremers EM, Alhan C, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Best Pract Res Clin Haematol. 2015 Mar;28(1):14-21. doi: 10.1016/j.beha.2014.11.003. Epub 2014 Nov 11. Review.

PMID:
25659726
13.

High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.

Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, van de Loosdrecht AA.

Br J Haematol. 2014 Oct;167(1):100-9. doi: 10.1111/bjh.12994. Epub 2014 Jun 30.

PMID:
24976502
14.

Fatigue in children: reliability and validity of the Dutch PedsQL™ Multidimensional Fatigue Scale.

Gordijn M, Cremers EM, Kaspers GJ, Gemke RJ.

Qual Life Res. 2011 Sep;20(7):1103-8. doi: 10.1007/s11136-010-9836-9. Epub 2011 Jan 19. Erratum in: Qual Life Res. 2011 Sep;20(7):1109. Suzanne Gordijn, M [corrected to Gordijn, M Suzanne].

Supplemental Content

Loading ...
Support Center